Earlybird Venture Capital

Earlybird Venture Capital is a pan-European venture capital firm founded in 1997 by Dr. Hendrik Brandis and Dr. Christian Nagel, headquartered in Berlin with additional offices in London, Milan, and Munich. The firm invests at Pre-Seed (20%), Seed (60%), and Series A (20%) stages, with initial ticket sizes up to €12M. It manages €2.5 billion in assets across multiple fund strategies, including its main tech fund and Earlybird Health. The firm's investment thesis is structured around three areas: AI applications, software infrastructure and foundation models, and deep tech and hardware. Its most recent vehicle, Fund VIII (€360M, closed 2026), is its largest to date and continues the early-stage European focus. Notable portfolio companies include UiPath, N26, Aleph Alpha, Snyk, Isar Aerospace, and Marvel Fusion. Earlybird operates an internal AI platform called EagleEye for deal sourcing and portfolio support, and has introduced a perpetual ownership model under which the firm remains fully owned by its active partners.